Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02692716 · ClinicalTrials.gov registry record · Phase 3
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,183
- Enrollment target
NCT02692716: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT02692716 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 3,183 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (312% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02692716, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,183 participants
- Enrollment target
Study Summary
This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.
Primary Outcome
Number of participants experiencing a first event of a MACE, defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.
Interventions
- DRUG placebo
- DRUG semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,183 participants |
| Start Date | 2017-01-17 |
| Est. Completion | 2018-09-25 |
| Phase | Phase 3 |
What the finished NCT02692716 record still lists
NCT02692716 is an interventional study that assigns participants to a tested intervention. Its 3,183 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (312% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02692716 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02692716 about?
NCT02692716 is a clinical study titled "A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes". This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.
What is the current status of trial NCT02692716?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,183 participants. The study started on 2017-01-17. Estimated completion is 2018-09-25.
What interventions are being tested in trial NCT02692716?
The interventions under investigation include: placebo (DRUG), semaglutide (DRUG).
Who is sponsoring clinical trial NCT02692716?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02692716's enrollment target sits among peer trials
3,183 74th of 2000 higher than 1,927 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02043457 · 3,200 participants
Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance
- NCT04045665 · 3,200 participants · Phase 3
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
- NCT05381766 · 3,200 participants · NA
Building Access to Food Through Systems and Solidarity
- NCT06042543 · 3,200 participants · NA
Novel, One Stop, Affordable, Point of Care and AI Supported System of Screening, Triage and Treatment Selection for Cervical Cancer in LMICs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI